EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expanding access to early phase trials: the CATCH-UP.2020 experience

Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, Anthony F Shields, Farshid Dayyani, Amitkumar Mehta, Janice M Mehnert, Jonathan Trent, Rodwell Mabaera, Margaret Mooney, Jeffrey A Moscow, James Doroshow und 4 weitere

JNCI Cancer Spectrum · 2023

DOI: 10.1093/jncics/pkac087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2023. Verfasst von Joaquina C Baranda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Kansas Cancer Center, Kansas City, KS, USA. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disparities in cancer outcomes persist for underserved populations; one important aspect of this is limited access to promising early phase clinical trials. To address this, the National Cancer Institute–funded Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP.2020) was created. We report the tools developed and accrual metrics of the initial year of CATCH-UP.2020 with a focus on racial, ethnic, geographic, and socioeconomically underserved populations.

Methods

CATCH-UP.2020 is a P30 supplement awarded to 8 National Cancer Institute–designated cancer centers with existing resources to rapidly open and accrue to Experimental Therapeutics Clinical Trials Network (ETCTN) trials with emphasis on engaging patients from underserved populations. Sites used patient-based, community-based, investigator-based, and program-based tools to meet specific program goals.

Results

From September 2020 to August 2021, CATCH-UP.2020 sites opened 45 ETCTN trials. Weighted average trial activation time for the 7 sites reporting this was 107 days. In the initial year, sites enrolled 145 patients in CATCH-UP.2020 with 68 (46.9%) representing racial, ethnic, rural, and socioeconomically underserved populations using the broader definition of underserved encompassed in the grant charge. During the initial year of CATCH-UP.2020, a time impacted by the COVID-19 pandemic, 15.8% (66 of 417) and 21.4% (31 of 145) of patients enrolled to ETCTN trials at network and at CATCH-UP sites, respectively, were from racial and ethnic minority groups, a more limited definition of underserved for which comparable data are available.

Conclusion

Targeted funding accelerated activation and accrual of early phase trials and expanded access to this therapeutic option for underserved populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansEthnicityMinority GroupsPandemicsClinical Trials as Topic

Autor:innen und Institutionen

  • Department of Medical Oncology, University of Kansas Cancer Center, Kansas City, KS, USA.
  • Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, KS, USA.
  • National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Division of Hematology/Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center-University of California Irvine, Irvine, CA, USA.
  • Division of Hematology and Oncology, Department of Internal Medicine, O'Neal Comprehensive Cancer Center-University of Alabama at Birmingham, Birmingham, AL, USA.

ORCID-Profile: Alexandra Thomas

Förderung

  • NCI NIH HHS
  • National Institute of Health

Zitieren

APA

Baranda, J. C., Diaz, F. J., Rubinstein, L., Shields, A. F., Dayyani, F., Mehta, A., Mehnert, J. M., Trent, J., Mabaera, R., Mooney, M., Moscow, J. A., Doroshow, J., Waters, B., Ivy, P., Gore, S. D., & Thomas, A. (2023). Expanding access to early phase trials: the CATCH-UP.2020 experience. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkac087

Vancouver

Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, et al. Expanding access to early phase trials: the CATCH-UP.2020 experience. JNCI Cancer Spectrum. 2023. doi:10.1093/jncics/pkac087

BibTeX
@article{Baranda2023,
  author = {Baranda, Joaquina C and Diaz, Francisco J and Rubinstein, Larry and Shields, Anthony F and Dayyani, Farshid and Mehta, Amitkumar and Mehnert, Janice M and Trent, Jonathan and Mabaera, Rodwell and Mooney, Margaret and Moscow, Jeffrey A and Doroshow, James and Waters, Brittany and Ivy, Percy and Gore, Steven D and Thomas, Alexandra},
  title = {Expanding access to early phase trials: the CATCH-UP.2020 experience},
  journal = {JNCI Cancer Spectrum},
  year = {2023},
  doi = {10.1093/jncics/pkac087}
}
Kostenlos starten →